Following a full submission
AWMSG advice |
|||
| Status: Recommended | |||
Midodrine hydrochloride (Bramox®) is recommended for use within NHS Wales for the treatment of severe orthostatic hypotension due to autonomic dysfunction when corrective factors have been ruled out and other forms of treatment are inadequate. |
|||
|
|||
Medicine details |
|||
| Medicine name | midodrine hydrochloride (Bramox®) | ||
| Formulation | 2.5 mg and 5 mg tablets | ||
| Reference number | 2650 | ||
| Indication | In adults for the treatment of severe orthostatic hypotension due to autonomic dysfunction when corrective factors have been ruled out and other forms of treatment are inadequate |
||
| Company | Brancaster Pharma Ltd | ||
| BNF chapter | Cardiovascular system | ||
| Submission type | Full | ||
| Status | Recommended | ||
| Advice number | 2915 | ||
| NMG meeting date | 09/09/2015 | ||
| AWMSG meeting date | 21/10/2015 | ||
| Ratification by Welsh Government | 17/11/2015 | ||
| Date of issue | 18/11/2015 | ||
| Date of last review | 21/03/2019 | ||
| Further information This recommendation also applies to the 10mg tablets and to generic midodrine licensed for the same indication |
|||